 |
12 Diseases |  |
14 Trials |
|
14 Trials |  |
489 News |  |
| 12345678» |
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Journal, HEOR, Patient reported outcomes: De-simplifying antiretroviral therapy from a single-tablet to a two-tablet regimen: Acceptance, patient-reported outcomes, and cost savings in a multicentre study. (Pubmed Central) - May 7, 2024
De-simplification from an STR to a TTR within the Dutch healthcare setting has been demonstrated as feasible, leads to significant cost reductions and should be discussed with every eligible person with HIV in the Netherlands.
- | abacavir / Generic mfg.
Journal: The anti-HIV drug abacavir stimulates ?-catenin activity in osteoblast lineage cells. (Pubmed Central) - Apr 9, 2024
Bone mineral density (BMD) loss in people living with HIV occurs with the initiation of combined antiretroviral therapy (cART), particularly with tenofovir disoproxil fumarate (TDF) containing cART...Primary human osteoblasts and male C57BL/6 mice were treated with individual antiretrovirals (ARVs) or a combination of ABC/DTG/lamivudine (3TC)...ABC, alone and as part of ABC/DTG/3TC, increased osteoblastic ?-catenin activity as indicated by increased TOPFlash activity, hypo-phosphorylated (active) ?-catenin staining, and ?-catenin targeted gene expression...Overall, our findings demonstrate that ABC activates Wnt/?-catenin signaling, but whether this leads to increased bone formation requires further study. Assessing the impact of ARVs on bone is critical to informing ARV selection and/or discovery of regimens that do not negatively impact the skeleton.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Emerging Integrase Resistance in the Perinatal Virtual Clinic: The Need for Protease Inhibitors (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_1329;
A second suppressed on nevirapine/3TC/ABC for 11 years simplified to DTG/3TC/ABC but failed 4 years later with an R263RK (intermediate DTG-R)...INSTI resistance is emerging in CALWHIV, most commonly in highly treatment experienced individuals from L/MIC. This highlights the global need for access to DRV/r, TXF and novel classes, including formulations for children <35kg.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Inflammatory Profile of B/F/TAF, DTG/ABC/3TC, and DTG+F/TAF Over 5 Years and Effects of Viral Blips (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_831;
This highlights the global need for access to DRV/r, TXF and novel classes, including formulations for children <35kg. Viral suppression was associated with significantly reduced inflammation in treatment-na
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
A Single Once Daily ABC/DTG/3TC Tablet Predicts Safe and Effective Exposures in Children 3 to (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_764;
Predicted drug exposures support the potential use of a single FDC of ABC/DTG/3TC DT in infants weighing 3-<6kg (aged ?4 weeks), with efficacy and safety expected to be comparable to prior pediatric studies in children ?6kg. The once daily single tablet treatment option may be a practical solution for infants with early HIV diagnosis.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Population Pharmacokinetics of ABC/DTG/3TC FDC to Support Dosing in Peds With HIV-1: IMPAACT 2019 (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_758;
This model-based approach leveraged existing pediatric data and models to confirm FDC ABC/DTG/3TC dosing for DT and Tablet using PK data collected in IMPAACT 2019. This analysis supports ABC/DTG/3TC FDC dosing in children weighing ?6 kg.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
IMMUNE COMPLEX-MEDIATED NEPHROPATHY AS AN INITIAL MANIFESTATION OF ACUTE HIV INFECTION: CASE REPORT (SAT-283; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1687;
Immune complex-mediated lesions typically occur after years of illness, usually in patients with good disease control. There are no reported cases in the literature of HIVICK as the initial renal manifestation of acute HIV infection.
- Treatment Persistence Among Treatment-Experienced People With HIV (PWH) Switching To Integrase Strand Transfer Inhibitor (INSTI)-Based HIV Antiretroviral Regimens () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1860;
Nearly one in 10 treatment-experienced PWH experienced a secondary switch in therapy. PWH initiating BIC/FTC/TAF were significantly less likely than those starting other INSTI-based regimens to subsequently switch.
- Antiretroviral Regimens Are Associated With Cognitive Function in People With HIV (Poster hall) - Mar 5, 2024 - Abstract #CROI2024CROI_515;
Tenofovir (including TAF or TDF) and FTC were common in such regimens in combination with either DRV+COBI, RPV, or EFV. Our findings suggest complex associations between ART regimens and cognition, such that specific ART combinations rather than individual agents are associated with cognition.
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Severe Hyponatremia With Subclinical Seizures in a Patient With Well Controlled HIV After Taking Nirmatrelvir-Ritonavir (Paxlovid (San Diego Convention Center, Area L (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3359;
Home medications included abacavir-lamivudine, dolutegravir, finasteride, and amlodipine...He was treated with levetiracetam and lacosamide with resolution of seizures but did not return to neurologic baseline... Although rare, severe hyponatremia is a known complication of Paxlovid
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Augmented least squares, a powerful chemometric approach for the spectroscopic analysis of the antiretroviral therapy abacavir, lamivudine and dolutegravir in their ternary mixture. (Pubmed Central) - Jan 15, 2024
Although rare, severe hyponatremia is a known complication of Paxlovid However, higher RRMSEP values around 5
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Journal: Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters. (Pubmed Central) - Jan 15, 2024
However, higher RRMSEP values around 5 Our results suggest that BIC/FTC/TAF could be a preferred regimen as initial therapy in HIV late presenters because of its high effectiveness and good tolerability.
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Journal: Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy. (Pubmed Central) - Nov 10, 2023
P3
Coronary microvascular function did not improve after switching from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/TAF. Registration URL: https://www.clinicaltrials.gov; unique identifier: NCT03656783.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
The effect of antiretroviral therapy Triumeq on a TDP-43 mouse model of ALS (Event Halle, Messe Basel, Ground Floor) - Nov 7, 2023 - Abstract #ALSMND2023ALS_MND_504;
However, these results highlight a therapeutic benefit of Triumeq to treat ALS. megan.dubowsky@flinders.edu.au
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Review, Journal: Biktarvy for the treatment of HIV infection: Progress and prospects. (Pubmed Central) - Nov 6, 2023
megan.dubowsky@flinders.edu.au Based on the accumulated evidence from HIV clinical trials and real-world studies, the clinical effectiveness of BIC
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Early virological failure with Cabotegravir plus Rilpivirine in clinical practice (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_1550;
In our case, probably the cause of VF was the pre-existence of NNRTI mutations together with low CAB concentrations. The availability of a baseline genotype, regardless of VF history or NNRTI exposure, may be key in making decisions to switch to CAB+RPV LA-2M.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Early virological failure with Cabotegravir plus Rilpivirine in clinical practice (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_1549;
In our case, probably the cause of VF was the pre-existence of NNRTI mutations together with low CAB concentrations. The availability of a baseline genotype, regardless of VF history or NNRTI exposure, may be key in making decisions to switch to CAB+RPV LA-2M.
- Tivicay (dolutegravir) / ViiV Healthcare
Incidence of Metabolic Syndrome in People living with HIV Starting ART with a Dolutegravir Based-Regimen vs Bictegravir Based-Regimen After 24 Weeks in Mexico (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_814;
The availability of a baseline genotype, regardless of VF history or NNRTI exposure, may be key in making decisions to switch to CAB+RPV LA-2M. Method :
- Tivicay (dolutegravir) / ViiV Healthcare
Incidence of Metabolic Syndrome in People living with HIV Starting ART with a Dolutegravir Based-Regimen vs Bictegravir Based-Regimen After 24 Weeks in Mexico (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_813;
Method : Method :
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
3-year analysis of emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second generation INSTIs in 2- and 3-drug regimens (Virostar study) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_728;
Sanger genotypic resistance assays were performed as part of standard clinical care at the time of a FL or SL VF in patients failing treatment with DTG/3TC, DTG/RPV, BIC/FTC/TAF and DTG/3TC/ABC. Conclusions :
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
3-year analysis of emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second generation INSTIs in 2- and 3-drug regimens (Virostar study) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_727;
Sanger genotypic resistance assays were performed as part of standard clinical care at the time of a FL or SL VF in patients failing treatment with DTG/3TC, DTG/RPV, BIC/FTC/TAF and DTG/3TC/ABC. Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
Impact of pre-existing HIV-1 primary and secondary reverse transcriptase and integrase resistance-associated mutations by next generation sequencing on virological response to dolutegravir (DTG)-containing regimens in antiretroviral-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_716;
Resistance analyses in the 9 subjects with VF did not reveal any emergent resistance to the study drugs. Analyses of virological outcomes at weeks 48 and 96 did not find a significant role of pre-existing resistance in any of the analyzed groups (Fig.2) Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
Impact of pre-existing HIV-1 primary and secondary reverse transcriptase and integrase resistance-associated mutations by next generation sequencing on virological response to dolutegravir (DTG)-containing regimens in antiretroviral-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_715;
Resistance analyses in the 9 subjects with VF did not reveal any emergent resistance to the study drugs. Analyses of virological outcomes at weeks 48 and 96 did not find a significant role of pre-existing resistance in any of the analyzed groups (Fig.2) Conclusions :
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bictegravir/emtricitabine/tenofovir alafenamide vs. other regimens for initial therapy in late presenters with AIDS-defining conditions. (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_496;
Analyses of virological outcomes at weeks 48 and 96 did not find a significant role of pre-existing resistance in any of the analyzed groups (Fig.2) Conclusions : Analyzing single regimens, we observed differences in the rate of virological suppression between BIC/FTC/TAF and DTG/ABC/3TC both at 24 (ORa [95%CI]: 0.17 [0.04
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bictegravir/emtricitabine/tenofovir alafenamide vs. other regimens for initial therapy in late presenters with AIDS-defining conditions. (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_495;
Analyzing single regimens, we observed differences in the rate of virological suppression between BIC/FTC/TAF and DTG/ABC/3TC both at 24 (ORa [95%CI]: 0.17 [0.04 Analyzing single regimens, we observed differences in the rate of virological suppression between BIC/FTC/TAF and DTG/ABC/3TC both at 24 (ORa [95%CI]: 0.17 [0.04
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_490;
Analyzing single regimens, we observed differences in the rate of virological suppression between BIC/FTC/TAF and DTG/ABC/3TC both at 24 (ORa [95%CI]: 0.17 [0.04 Purpose :
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_489;
Purpose : Purpose :
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment. (Pubmed Central) - Sep 13, 2023
Purpose : The patient had baseline suppressed HIV viral load on fixed dose combination dolutegravir/abacavir/lamivudine when once-weekly rifapentine 900
- Rates and reasons for antiretroviral switches with implicated drug associations: a post-COVID 10-year comparison (ETIUDA) - Sep 10, 2023 - Abstract #EACS2023EACS_311;
Other reasons included simplification (17%), of which 40% were Triumeq to Dovato, virological failure (3%) and other...Bictegravir, raltegravir, darunavir and other antiretrovirals each accounted for 4%, and the associated drug was unknown in 1%...Efavirenz is still associated with the highest number of toxicity-related switches, however, switches from tenofovir have doubled, possibly due to the introduction of tenofovir alafenamide and two-drug regimens. The introduction of dolutegravir and doravirine has highlighted new toxicities.
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Journal, Real-world evidence, Real-world: Lipid profile changes associated with antiretroviral therapies in a real-world cohort. (Pubmed Central) - Sep 8, 2023
The introduction of dolutegravir and doravirine has highlighted new toxicities. The lipid profile among elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate group worsened throughout the follow-up, both in na
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of Antiretroviral Drug Resistance Mutations (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3001;
- Retrospective Study Comparing the Rate of HIV Blips With Combined Antiretroviral Therapy (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2974;
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion date: FLAIR: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (clinicaltrials.gov) - Aug 31, 2023
P3, N=631, Active, not recruiting, Sponsor: ViiV Healthcare
The lipid profile among elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate group worsened throughout the follow-up, both in na Trial completion date: Feb 2024 --> Dec 2026
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
P1/2 data, PK/PD data, Clinical Trial,Phase I, Journal: Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. (Pubmed Central) - Aug 9, 2023
P1/2
Dosing of abacavir, dolutegravir, and lamivudine was confirmed in children weighing 6 kg to less than 40 kg, and both FDC formulations were safe, well tolerated, and efficacious through 24 weeks of treatment. These findings support global efforts to expand the availability of FDC abacavir, dolutegravir, and lamivudine to children with HIV.
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Journal, HEOR, Real-world evidence, Real-world: Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens. (Pubmed Central) - Aug 8, 2023
These findings support global efforts to expand the availability of FDC abacavir, dolutegravir, and lamivudine to children with HIV. Dolutegravir/lamivudine had the lowest healthcare costs of BIC/FTC/TAF, EVG/COBI/FTC/TAF, and DRV/COBI/FTC/TAF, and the lowest pharmacy costs of all regimens, in unadjusted and adjusted analyses and by treatment experience, supporting the economic benefits of DTG/3TC as an initial or switch regimen for HIV-1.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Disseminated Histoplasmosis: A Gastrointestinal Manifestation (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3946;
It is important to note that HIV patients with HBV who stop antiretroviral agents that have activity against HBV (like Truvada, or Triumeq), are at higher risk of hep B reactivation, particularly HBV-related immune reconstitution. Figure: Patient's EGD which showed ulcerated mass with active bleeding in the 2nd portion of duodenum.
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
P4 data, Journal: A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1. (Pubmed Central) - Jun 5, 2023
Figure: Patient's EGD which showed ulcerated mass with active bleeding in the 2nd portion of duodenum. Results of this PMS study showed that abacavir/dolutegravir/lamivudine administered as highly active antiretroviral therapy was well tolerated and effective in patients with HIV-1 infection.
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Journal: Effect of Food on the Pediatric Dispersible Tablet Formulations of TRIUMEQ and DOVATO in Healthy Adult Participants. (Pubmed Central) - May 27, 2023
Safety observations were similar for both treatments, either in the fed or fasted state. Both TRIUMEQ DT and DOVATO DT formulations can be administer with or without food.
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Journal: Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. (Pubmed Central) - May 18, 2023
P3
Both TRIUMEQ DT and DOVATO DT formulations can be administer with or without food. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir [DTG]/abacavir/lamivudine) and 1490 (vs DTG
- Probability of single tablet regimens BIC/FTC/TAF, E/C/F/TAF, RPV/FTC/TAF, DTG/RPV or DTG/ABC/3TC discontinuation at 18 months in real life settings in the ANRS-CO3 - AquiVIH-NA cohort () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1476;
The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir [DTG]/abacavir/lamivudine) and 1490 (vs DTG Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- || Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Review, Journal: An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1. (Pubmed Central) - Mar 25, 2023
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). These results suggest that the 2-drug regimen DTG?+?3TC offers comparable and durable efficacy with fewer serious adverse events vs BIC/FTC/TAF and DTG/ABC/3TC through 144
- bictegravir (GS-9883) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Cost-Utility of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Naive Patients over 18 Years of Age Living with Human Immunodeficiency Virus Type 1 Infection, from the Colombian () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1650;
BIC/TAF/FTC is cost-effective compared to DTG/TAF/FTC and EVG/c/TAF/FTC with an incremental cost-effectiveness ratios of COP 25,423,858/QALY and COP 46,848,852/QALY, respectively. In naive patients over 18 years of age living with HIV-1 infection, BIC/TAF/FTC versus other triple combination antiretroviral therapies is a cost-effective technology for the Colombian health system.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare, Fuzeon (enfuvirtide) / Roche
CLINICAL PHARMACEUTICAL CHALLENGES OF A BONE MARROW TRANSPLANT (BMT) PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV): A PAEDIATRIC PHARMACISTS PERSPECTIVE (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1708;
In naive patients over 18 years of age living with HIV-1 infection, BIC/TAF/FTC versus other triple combination antiretroviral therapies is a cost-effective technology for the Colombian health system. Admitted for BMT.Pharmacist-led ARV management plan in place within the conditioning protocol, with MDT approved recommendations if;Mucositis develops to reduce enteral absorptionNasogastric (NG) feeding or oral electrolytes requiredManagement plan created liaising with HIV team.Patient continued on current ARV regimen:Triumeq
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
P4 data, Journal: Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286). (Pubmed Central) - Dec 21, 2022
Beyond treatment simplicity and tolerability, tailored interventions addressing stigma and social determinants of health are still needed. The numerous challenges we encountered illustrate how randomised trials may not be the best approach for assessing adherence interventions in vulnerable populations.
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Interesting study from our CVIS group Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People … https://t.co/V6vwzafwvi (Twitter) - Dec 20, 2022
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Retrospective data, Journal: Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study. (Pubmed Central) - Dec 16, 2022
In the real world, the risk of regimen discontinuation was higher in PLWAH on coformulated DTG/ABC/3TC than in those on B/F/TAF, with no difference in viral suppression or virological failure. Given the findings concerning the effect of same-day ART prescription and AOIs on AR-related regimen discontinuation, individualized approaches to PLWAH are necessary.
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, abacavir/lamivudine / Generic mfg.
Dolutegravir abacavir lamivudine can surpess to below 50 VL in only 16 weeks ❤️. Does the abacavir play significant role? I am having TDF instead of it (Twitter) - Dec 9, 2022
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Retrospective data, Journal: Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study). (Pubmed Central) - Nov 15, 2022
After ART initiation patients gain weight regardless of the regimen they take. Weight gain is associated with AIDS and the use of TAF/FTC/EVG/c.
- | abacavir / Generic mfg.
Journal: Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report. (Pubmed Central) - Nov 9, 2022
Clinicians should always be cognizant of this adverse reaction whenever they initiate an abacavir-containing therapy. We would recommend that studies be done in our setting to verify the prevalence of HLA-B*57:01.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report. (Pubmed Central) - Nov 9, 2022
This case illustrates how poorly-fit drug-resistant viruses wax and wane alongside erratic treatment adherence and are easily misdiagnosed by Sanger sequencing. We recommend next-generation sequencing to improve the clinical management of incomplete virological suppression with dolutegravir.